• Remote Ischemic Postconditioning: Ketone Body Neuroprotectio

  2026-06-26

  The referenced study demonstrates that remote ischemic postconditioning (RIPostC) confers neuroprotection after ischemic stroke by promoting ketone body-induced inhibition of ferroptosis. These findings clarify a previously underexplored mechanism linking energy metabolism, ferroptotic cell death, and stroke recovery, with significant implications for metabolic and epigenetic research strategies.

• miR-3180 Suppresses HCC by Targeting Lipid Synthesis and Upt

  2026-06-26

  Hong et al. (2023) identify miR-3180 as a crucial inhibitor of hepatocellular carcinoma (HCC) growth and metastasis through direct suppression of SCD1 and CD36, key regulators of lipid synthesis and uptake. This finding highlights a new therapeutic and prognostic avenue in HCC by modulating metabolic pathways central to tumor progression.

• Structural Determinants of Cyclosporin Variants in Mitochond

  2026-06-25

  This study rigorously compares cyclosporin B–E variants, integrating NMR and molecular dynamics to correlate structural flexibility with their ability to inhibit the mitochondrial permeability transition pore. The findings highlight that only variants with sufficient backbone flexibility—like Cyclosporin A—retain potent mitochondrial pore inhibition, providing mechanistic insight crucial for immunosuppression and mitochondrial research.

• Angiotensin II-HIF-1α-HILPDA Axis Drives NPC Radioresistance

  2026-06-25

  This study uncovers how local angiotensin II (Ang II) signaling in nasopharyngeal carcinoma (NPC) suppresses ferroptosis and enhances radioresistance via the HIF-1α-HILPDA axis. The findings establish actionable molecular targets and suggest that combined inhibition of Ang II signaling and induction of ferroptosis may improve radiotherapy outcomes in NPC.

• SAG: Smoothened Receptor Agonist for Precision Pathway Activ

  2026-06-24

  Smoothened Agonist (SAG) delivers targeted and reproducible Hedgehog pathway activation for neuroregeneration, stem cell, and developmental studies. This in-depth guide distills the latest advances in experimental workflows, assay troubleshooting, and protocol optimization, empowering researchers to maximize translational impact with SAG from APExBIO.

• SP2509: Precision Lysine-Specific Demethylase 1 Antagonist W

  2026-06-23

  SP2509, a potent Lysine-specific demethylase 1 antagonist from APExBIO, transforms acute myeloid leukemia and cancer epigenetics research by enabling robust, reproducible induction of apoptosis and differentiation. This guide delivers actionable, evidence-based workflows and troubleshooting tips to maximize experimental rigor and translational relevance.

• Vacuolin-1: Dissecting Lysosomal Exocytosis in Disease Model

  2026-06-23

  Explore how Vacuolin-1, a potent lysosomal exocytosis inhibitor, enables precise investigation into membrane repair and signaling dysfunction in disease models. This article uniquely bridges recent mechanistic findings with advanced assay design, offering actionable insights beyond existing protocols.

• Estradiol and GPR30 Activation Restore Immune Function After

  2026-06-22

  This study demonstrates that 17β-estradiol (E2) restores splenic CD4+ T lymphocyte function following hemorrhagic shock by inhibiting endoplasmic reticulum stress (ERS), with effects mediated through ERα and GPR30, but not ERβ. These findings clarify the non-classical estrogen signaling pathways involved in immune recovery post-trauma, highlighting mechanistic targets for translational research.

• Oseltamivir Acid: Translational Leverage in Influenza and On

  2026-06-22

  This in-depth analysis explores the mechanistic and translational dimensions of Oseltamivir acid, highlighting its dual role as an influenza neuraminidase inhibitor and an emerging adjunct in oncology research. It integrates species-specific metabolism, prodrug activation, and resistance challenges, offering actionable guidance for translational researchers and bridging insights from recent humanized mouse studies.

• G-1: Selective GPR30 Agonist Workflows in Cancer & Cardiac M

  2026-06-21

  G-1 (CAS 881639-98-1) stands out as a selective GPR30 agonist, enabling robust dissection of estrogenic signaling in oncology and cardiovascular research. Its nanomolar potency and DMSO-ready solubility streamline experimental setup and data reproducibility where classical ER ligands fall short.

• NEDD4L E3 Ligase Suppresses Colorectal Cancer Liver Metastas

  2026-06-20

  This study identifies NEDD4L as a critical E3 ubiquitin ligase that restricts colorectal cancer liver metastasis by targeting PRMT5 for degradation. The findings reveal a mechanistic link between NEDD4L, PRMT5, and the AKT/mTOR pathway, offering new insights for metastasis prevention strategies.

• Cyclopamine: Precision Hedgehog Signaling Inhibitor Workflow

  2026-06-19

  Cyclopamine’s potent Smoothened receptor antagonism enables researchers to dissect Hedgehog pathway functions in cancer and developmental models with reproducible, biologically relevant outcomes. Explore detailed workflows, troubleshooting strategies, and the latest epigenetic insights to maximize the value of Cyclopamine from APExBIO in translational research.

• Cy5 TSA Fluorescence System Kit: Pushing Spatial Proteomics

  2026-06-19

  Explore how the Cy5 TSA Fluorescence System Kit elevates spatial proteomics workflows, with a unique focus on single-cell-type resolution and practical assay optimization. This in-depth analysis reveals scientific mechanisms and applications beyond standard immunohistochemistry.

• X-Gal in Molecular Cloning: Precision, Workflows, and Troubl

  2026-06-18

  X-Gal (5-bromo-4-chloro-indolyl-β-D-galactopyranoside) is the gold-standard chromogenic substrate for blue-white colony screening, enabling rapid identification of recombinant clones. This article details optimized experimental workflows, protocol parameters, and troubleshooting strategies, with insights from the latest neuroscience research and APExBIO's high-purity offering.

• Optimizing Apoptosis Assays with TNF-alpha, Recombinant Muri

  2026-06-18

  This article addresses key challenges in apoptosis and inflammation research, focusing on reproducibility and sensitivity when using TNF-alpha recombinant murine protein (SKU P1002) as a cell culture cytokine treatment. Integrating scenario-driven Q&A and validated data, it demonstrates how SKU P1002 from APExBIO offers reliable, high-activity solutions for cell-based assays.

16832 records 1/1123 page Next 12345 下5页 Last page